More Promising Pediatric News on Beyfortus

More Promising Pediatric News on Beyfortus

As the 2026 year begins and the RSV season is midway through, there is some encouraging news regarding infection prevention in infants given Beyfortus ( nirsevimab-alip ).  It appears that in addition to outstanding protection afforded to Beyfortus ( nirsevimab ) recipents against respiratory syncytial virus ( RSV ), it may also provide some protection against other lower respiratory infections as well.  Find below some information from the report published in JAMA pediatrics

This real-world meta-analysis of 263,755 infants (≤24 months) confirms the high efficacy of nirsevimab:

·   76% Effectiveness against RSV-related LRTI emergency department visits.

·   62% Effectiveness against all-cause LRTI-related hospitalizations.

·   48% Effectiveness against all-cause LRTI-related ED visits.

·   Note: No significant association was found regarding all-cause hospitalizations (non-respiratory).

Healthcare providers may order Beyfortus directly through VaccineShop. Important discounts may be accessed for free through a membership in Physicians Buying Group/PracticeWell. Saving money on vaccines and finding discounts on just about everything for our members is only part of the important support services PBG/PracticeWell provides!